Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials (China)

This article was originally published in PharmAsia News

Executive Summary

Sinovac Biotech has reported no serious adverse events from the Phase I and Phase II clinical trials for its vaccine designed to prevent the deadly H5N1 strain of bird flu. Sinovac had been given official approval to conduct the trials in April by the China State Food and Drug Administration. The first Phase II trial tested the vaccine on 401 patients ranging in age from 18 to 65. All participants were given either a 5 ug, 10 ug, or 15 ug dose of the vaccine. The second Phase I and Phase II trials divided 160 volunteers ranging from age three to 70 into four age groups. The same dosing rules applied to these groups with the addition of a 30 ug dose. Sinovac has also announced it will soon be reporting its official financial results for the third quarter. The Chinese company, which specializes in developing vaccines, already has treatments approved for Hepatitis A and B as well as normal influenza. (Click here for more

You may also be interested in...



China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel